CandlesenseCandlesense
NBIX•benzinga•

Neurocrine Biosciences Reports Patient-Reported Outcome Data From The KINECT-PRO Study Of INGREZZA; Says 'Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures,'

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 27, 2025 by benzinga

← Back to NBIX News
    Neurocrine Biosciences Reports Patient-Reported Outcome Data From The KINECT-PRO Study Of INGREZZA; Says 'Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures,' | NBIX Stock News | Candlesense